ImmunoGen, Inc. (IMGN) Announces Favorable Initial Safety And Response Findings For CD38-Targeting Anticancer Compound, SAR650984
12/9/2013 10:12:08 AM
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted, antibody-based anticancer therapeutics, today announced the first clinical findings with SAR650984 reported in an oral presentation at the ASH annual meeting. The data are from an ongoing Phase I trial assessing this CD38-targeting therapeutic antibody in patients with CD38-positive MM or other hematologic malignancy. SAR650984 was initially developed by ImmunoGen with the Company’s target evaluation and antibody development expertise and was licensed to Sanofi as part of a broader collaboration between the companies.
Help employers find you! Check out all the jobs and post your resume.
comments powered by